Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå : Á¦Ç° À¯Çü, ºÐ¸®, ¼¼Æ÷ À¯Çü, ¿ëµµ, ±¹°¡ ¹× Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2023-2030³â)
Human Primary Cells Market with COVID-19 Impact Analysis, By Product Type, By Separation, By Cell Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1299773
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2023³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 323 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,516,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,462,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,852,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ÀÇ ÇÏÀ̶óÀÌÆ®

Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå ±Ô¸ð´Â 2022³â 13¾ï 6,070¸¸ ´Þ·¯·Î 2023³âºÎÅÍ 2030³â±îÁö 11.5%ÀÇ CAGR·Î È®´ë

Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - ½ÃÀå ¿ªÇÐ:

ÃÊ´ë ¼¼Æ÷ ½ÃÀåÀÇ ¼ºÀå ¹è°æ¿¡´Â ³ëÀÎ Àα¸ÀÇ Áõ°¡, ¿¬±¸ °³¹ßÀÇ ¹ßÀü, ¸¸¼º Áúȯ ȯÀÚÀÇ Áõ°¡°¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ ½ÃÀåÀº ÷´Ü °Ë»ç ¹× ÀǾàǰ °³¹ß·Î Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀåÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¿øÀÚÀç °¡¿ë¼º Á¦ÇѰú °í°¡ÀÇ °øÁ¤Àº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¶ÇÇÑ, ÀÏÂ÷ ¼¼Æ÷ ¹è¾çÀº ½Å¾àÀÇ ¼¼Æ÷ µ¶¼ºÀ» È®ÀÎÇϱâ À§ÇØ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, Àΰ£ ÃÊ´ë ¼¼Æ÷´Â È­ÇÐÁ¦Ç°, È­Àåǰ ¹× ½Å¾àÀÇ È¿°ú¸¦ Å×½ºÆ®Çϱâ À§ÇØ µ¿¹° ¸ðµ¨ ´ë½Å¿¡ »ç¿ëµË´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀº Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. Àΰ£ ÃÊ´ë ¼¼Æ÷´Â ¿¬±¸ÀÚµéÀÌ °¨¿°º´À» ÀÌÇØÇϱâ À§ÇØ »ç¿ëÇÕ´Ï´Ù. Ư¼ºÈ­µÇ°í Ç¥ÁØÈ­µÈ »óÇǼ¼Æ÷ ¹è¾ç ¸ðµ¨Àº Äڷγª¹ÙÀÌ·¯½º°¡ ÆÄ±«ÇÑ ¹°¸®Àû À庮À» ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¸ðµ¨Àº È£Èí±âÀÇ Æ¯¼º°ú ±â´ÉÀ» ¸ð¹æÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, ¿¬±¸ °á°ú¸¦ ÀÇ·á ÀÀ¿ëÀ¸·Î ÀüȯÇÒ ¼ö ÀÖ´Â µ¹ÆÄ±¸°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®:

¼¼°è Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀåÀº Á¦Ç° À¯Çü, ºÐ¸®, ¼¼Æ÷ À¯Çü, ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Ç° À¯Çü¿¡ µû¶ó ½ÃÀåÀº Àΰ£ ÃÊ´ë ¼¼Æ÷, ½Ã¾à ¹× º¸ÃæÁ¦, ¹èÁö µî ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ½Ã¾à ¹× º¸ÃæÁ¦ ºÐ¾ß°¡ ½ÃÀåÀ» Á¡À¯ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àΰ£ ÃÊ´ë ¼¼Æ÷´Â ½Ã¾à ¹× º¸ÃæÁ¦ÀÇ Á¦Á¶ ¹× ¿¬±¸¿¡¼­ ÀÏ»óÀûÀÎ ÀÀ¿ë¿¡ °ü¿©ÇÕ´Ï´Ù. ½Ã¾à°ú º¸ÃæÁ¦´Â Àΰ£ ÃÊ´ë ¼¼Æ÷°¡ ¼ºÀåÇϱâ À§ÇØ ±úÁö±â ½±±â ¶§¹®¿¡ ¸Å¿ì Áß¿äÇÑ °ÍÀ¸·Î °£Áֵ˴ϴÙ.

½ÃÀåÀº ºÐ¸®¸¦ ±âÁØÀ¸·Î ÃßÃâ¹ý, È¿¼Ò ºÐÇØ¹ý, ±â°èÀû ºÐ¸®¹ý ¹× ±âŸ·Î ³ª´¹´Ï´Ù. È¿¼Ò ºÐÇØ ¹æ¹ýÀº ¿¹Ãø ±â°£ µ¿¾È ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ´Â Àΰ£ ÃÊ´ë ¼¼Æ÷ÀÇ ºÐ¸®¿¡¼­ È¿¼Ò ºÐÇØ¹ýÀÌ ´Ù¸¥ ±â¼úÀ» ´ëüÇÏ¿© ºñ±³Àû ºü¸£°í, ´ëÇ¥ ½Ã·áÀÇ ¼öÀ²ÀÌ ³ô°í, ¹è¾ç¹°¿¡ ´ëÇÑ ¼Õ»óÀÌ Àû´Ù´Â ÀåÁ¡À¸·Î ÀÎÇØ È¿¼Ò ºÐÇØ¹ýÀÌ ³ôÀº Æò°¡¸¦ ¹Þ°í Àֱ⠶§¹®ÀÔ´Ï´Ù.

½ÃÀåÀº ¼¼Æ÷ À¯Çü¿¡ µû¶ó µ¿¹°¿ë°ú ÀÎü¿ëÀ¸·Î ³ª´¹´Ï´Ù. µ¿¹° ºÐ¾ß°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹é½Å °³¹ßÀ» À§ÇØ µ¿¹° À¯·¡ Àΰ£ ÃÊ´ë ¼¼Æ÷ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â Á¶Á÷¹è¾ç ¹× Á¶Á÷°øÇÐ, ¹é½Å »ý»ê, À¯ÀüÀÚ Ä¡·á ¹× Àç»ýÀÇ·á, µ¶¼º½ÃÇè ¹× ¾à¹° ½ºÅ©¸®´×, ¹ÙÀÌ·¯½ºÇÐ, ¾Ï ¿¬±¸, Áٱ⼼Æ÷ Ä¡·á, ¸ðµ¨ ½Ã½ºÅÛ, »êÀüÁø´Ü ¹× ±âŸ 9°¡Áö Ä«Å×°í¸®·Î ºÐ·ùµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¹é½Å »ý»ê ºÐ¾ß°¡ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, BÇü °£¿°, È«¿ª µî ´Ù¾çÇÑ ¹é½Å »ý»ê¿¡ »ç¿ëµÇ´Â ¹ÙÀÌ·¯½º¸¦ »ý»êÇϱâ À§ÇØ µ¿¹° ÃÊ´ë ¹è¾çÀ» Ȱ¿ëÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - °æÀï »óȲ:

Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀåÀº ´Ù¾çÇÑ ¸é¿ª °áÇÌ ÁúȯÀÇ Ä¡·á¿¡ Àΰ£ ÃÊ´ë ¼¼Æ÷¸¦ Ȱ¿ëÇÏ¿© ´õ ³ªÀº Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ È°¹ßÇÑ ÅõÀÚ·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿ÀÀǾàǰ ¹× »ý¸í°øÇÐ ºÐ¾ßÀÇ ¼ºÀå°ú ÇÔ²² ÀÇÇÐ ¿¬±¸ÀÚµéÀº ¾Ç¼º ¾Ï Ä¡·á¸¦ À§ÇØ Àΰ£ ¹× µ¿¹° Á¶Á÷¿¡¼­ äÃëÇÑ Àΰ£ ÃÊ´ë ¼¼Æ÷¸¦ »ç¿ëÇÏ´Â ¿¬±¸¸¦ °è¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷µéÀº ½ÃÀå ¼öÀÍÀ» ³ôÀ̱â À§ÇØ ½ÅÁ¦Ç° Ãâ½Ã, M&A, R&D ºñ¿ë, ÆÄÆ®³Ê½Ê, Á¦ÈÞ µîÀÇ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 8¿ù Axol Bioscience Ltd´Â CENSO Biotechnologies¿ÍÀÇ ÇÕº´À» ¹ßÇ¥Çß½À´Ï´Ù. ÇÕº´ ÈÄÀÇ »ç¾÷ü´Â ¼­ºñ½º ¼Ö·ç¼Ç ¹× Á¦Ç° ºÐ¾ßÀÇ ¼±µµÀûÀÎ °ø±Þ¾÷ü°¡ µÉ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, °ËÁõµÈ Áï½Ã »ç¿ë °¡´ÉÇÑ ¼¼Æ÷ÁÖ, °­·ÂÇÑ ±â´É µ¥ÀÌÅÍ, ¸ÂÃãÇü ±â´É ¹× ±¤¹üÀ§ÇÑ Àü¹® Áö½ÄÀ» °®Ãá ÀÏ·ÃÀÇ ¼­ºñ½º¸¦ °í°´¿¡°Ô ºü¸¥ ¸®µå ŸÀÓÀ¸·Î Á¦°øÇÏ°Ô µÉ °ÍÀÔ´Ï´Ù.

¿¬±¸ÀÇ ÁÖ¿ä Æ¯Â¡

Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå¿¡ ´ëÇÑ ÀÌ Á¶»ç º¸°í¼­´Â 2022³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ½ÃÀå ±Ô¸ð, ¿¬Æò±Õ ¼ºÀå·ü(CAGR %), ÃßÁ¤ ¹× ¿¹Ãø(2023-2030³â)À» Á¦°øÇÕ´Ï´Ù.

ÀÌ Á¶»ç º¸°í¼­´Â ´Ù¾çÇÑ ºÎ¹®/±¹°¡¿¡ °ÉÃÄ ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â Àüü º¸°í¼­¿¡¼­ ½Å±Ô ÅõÀÚ ±âȸ, ±âÁ¸ ±â¾÷ÀÌ Á÷¸éÇÑ °úÁ¦, Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå¿¡¼­ Áö¼Ó°¡´ÉÇÑ ¼ºÀå ¿äÀÎÀ» È®ÀÎÇß½À´Ï´Ù.

COVID-19°¡ Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå ±Ô¸ð, ¿¹Ãø, CAGR ¹× ½ÃÀå ¿ªÇп¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ ¿¬±¸ ¹üÀ§¿¡¼­ ÀÚ¼¼È÷ ³íÀÇÇϰí, Äڷγª ÀÌÈÄ Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ ÀλçÀÌÆ®µµ ´Ù·ç°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â »ç¿ëÀÚ¿¡°Ô Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ °üÁ¡À» Á¦°øÇϱâ À§ÇØ Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀåÀÇ °æÀï »óȲ°ú ÁÖ¿ä Çõ½Å°¡ ºÐ¼®µµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ½ÃÀå ±Ô¸ð, ¼ºÀå·ü, ¸Å·Âµµ¸¦ ±âÁØÀ¸·Î ¸ðµç »ê¾÷ ºÎ¹®À» º¥Ä¡¸¶Å·ÇÏ´Â ¼ºÀå Àü¸Á ¸ÅÇÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä ½ÃÀå Âü¿©¾÷üµéÀÇ »ó¼¼ÇÑ ±â¾÷ °³¿ä¸¦ Á¦°øÇÏ¿© Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ±â¾÷µéÀÇ À繫 Á¤º¸ ¹× Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê¸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

¶ÇÇÑ, ÀÌ º¸°í¼­´Â ¼¼°è»Ó¸¸ ¾Æ´Ï¶ó Áö¿ªÀû Â÷¿ø¿¡¼­ ½ÃÀå¿¡ Âü¿©ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÇ ÁÖ¿ä ÀμöÇÕº´, Á¦ÈÞ ¹× ÇÕÀÛÅõÀÚ, ½ÅÁ¦Ç° Ãâ½Ã, ¿¬±¸°³¹ß, Áö¿ªÀû ÁøÃâ¿¡ ´ëÇØ¼­µµ ¼³¸íÇÕ´Ï´Ù.

Àΰ£ ÃÊ´ë ¼¼Æ÷ ¼¼°è ½ÃÀå º¸°í¼­´Â ÁÖ·Î °ø±Þ ¾÷ü, ÅõÀÚÀÚ, ½Å±Ô ÁøÀÔÀÚ, À¯Åë ¾÷ü, ±ÝÀ¶ ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ »ê¾÷ ¿¬±¸

Á¦5Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå »óȲ

Á¦7Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - Á¦Ç° À¯Çüº°

Á¦8Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - ºÐ¸®º°

Á¦9Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - ¼¼Æ÷ À¯Çüº°

Á¦10Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - ¿ëµµº°

Á¦11Àå Àΰ£ ÃÊ´ë ¼¼Æ÷ ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - Àΰ£ ÃÊ´ë ¼¼Æ÷ »ê¾÷

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§Àû Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Human Primary Cells market size was valued at USD 1,360.7 Million in 2022, expanding at a CAGR of 11.5% from 2023 to 2030.

Human Primary Cells are also known as mature cells extracted from living tissues of humans and animals after that processed to establish them for utilization in appropriate cell therapies. Additionally, Human Primary Cells are also used in several applications such as cancer research, 3D cell culture, tissue replacement, stem cell therapy, and virology. 3D cell culture is increasingly used by researchers to study cell biology and biochemistry, cell-pathogen interactions, drug effects, and cell signaling.

Human Primary Cells Market- Market Dynamics:

The primary cell market growth is attributed to the increasing geriatric population, advancements in development and research, and a rise in cases of chronic diseases. Additionally pharmaceutical market is growing significantly in advanced testing and drug development. This in turn projected to facilitate increased adoption of the Human Primary Cells market. However, restrictions implemented for the utilization of raw materials and expensive processes are the major factors hindering the market growth during the forecast period.

Moreover, primary cell cultures are used to identify the cytotoxicity of new drugs. Furthermore, Human Primary Cells are used in the place of animal models to test the effects of chemicals, cosmetics, and new drugs. These are some major factors expected to drive market growth. The COVID-19 pandemic has impacted the Human Primary Cells market positively. Human Primary Cells are used by researchers for understanding the infection. Characterized and standardized epithelium cell culture models are helping to understand the physical barrier devastated by the coronavirus. The models can assist mimic the properties and functions of the respiratory tract which leads to a breakthrough for a research outcome moving into a medical application

Human Primary Cells Market- Segmentation Analysis:

The global Human Primary Cells market is segmented on the basis of product type, separation, cell type, application, and region.

The market is divided into three categories based on product type: Human Primary Cells, reagents and supplements, and media. The reagents and supplements sector is expected to possess the market. Human Primary Cells are involved in reagents and supplements' routine application in manufacturing and research. The reagents and supplements are considered very crucial as Human Primary Cells are fragile for their growth.

The market is divided into three categories based on separation: explant method, enzymatic degradation, mechanical separation, and others. The enzymatic degradation sector is likely to maintain its dominance during the forecast period. This is partly due to its high preference at the place of other techniques for the separation of Human Primary Cells owing to its advantages such as comparatively fast, high yield of a representative sample, and less damage to cultures.

The market is divided into two categories based on cell type: animal and human. The animal sector is expected to hold the largest market share. For vaccine development, increasing the application of animal-origin Human Primary Cells are essential factor propelling the segment growth.

The market is divided into nine categories based on application: tissue culture & tissue engineering, vaccine production, gene therapy and regenerative medicine, toxicity testing & drug screening, virology, cancer research, stem cell therapy, model system, prenatal diagnosis, and others. The vaccine production sector is expected to dominate the market over the forecast period. Rising use of primary animal culture for the production of virus that is later utilized for producing various vaccines including hepatitis B and measles.

Human Primary Cells Market-Competitive Landscape:

The Human Primary Cells market is rapidly driven globally by robust investment in research and development activities for the increment of better therapies where Human Primary Cells can be utilized to treat various immunodeficiency disorders. Additionally, with The growth in biopharmaceutical and biotechnology sectors, medical researchers are continuously working on using Human Primary Cells from human and animal tissues for the treatment of malignant cancers. Moreover, key players are adopting strategies such as new product launches, mergers & acquisitions, R&D spending, partnerships, and collaboration to enhance their market revenue. For instance, in August 2021, Axol Bioscience Ltd announced its merger with CENSO Biotechnologies. The merged entity will become a leading provider of service solutions and products. Additionally, it will provide customers with validated ready-to-use cell lines and a suite of services with robust functional data, customization capabilities, and broader expertise, all with shorter lead times.

Key features of the study:

This proposed research study on Human Primary Cells market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year.

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Human Primary Cells market.

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Human Primary Cells market.

Impact of COVID-19 on Human Primary Cells market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Human Primary Cells market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the Human Primary Cells market, we have also included competitive landscape and key innovator analysis for Human Primary Cells market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

The report offersdetailed company profiling featuring major market participantswhich will help users to understand their financial information and strategic initiatives of players operating in the Human Primary Cells market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

The global Human Primary Cells market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HUMAN PRIMARY CELLS MARKET KEY PLAYERS

GLOBAL HUMAN PRIMARY CELLS MARKET, BY PRODUCT TYPE

GLOBAL HUMAN PRIMARY CELLS MARKET, BY SEPARATION

GLOBAL HUMAN PRIMARY CELLS MARKET, BY CELL TYPE

GLOBAL HUMAN PRIMARY CELLS MARKET, BY APPLICATION

GLOBAL HUMAN PRIMARY CELLS MARKET, BY REGION

Table of Contents

1. Human Primary Cells Market Overview

2. Executive Summary

3. Human Primary Cells Key Market Trends

4. Human Primary Cells Industry Study

5. Human Primary Cells Market: COVID-19 Impact Analysis

6. Human Primary Cells Market Landscape

7. Human Primary Cells Market - By Product Type

8. Human Primary Cells Market - By Separation

9. Human Primary Cells Market - By Cell Type

10. Human Primary Cells Market - By Application

11. Human Primary Cells Market- By Geography

12. Key Vendor Analysis- Human Primary Cells Industry

13. 360 Degree AnalystView

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â